SEC Form 4 · accession 0001209191-19-017231
TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Deborah A Griffin
Officer — Chief Accounting Officer
Period of report
Mar 4, 2019
Accepted (ET)
Mar 6, 2019 · 7:15 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818686
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF1,F2,F3 | — | Mar 4, 2019 | A | 19,321 | A | — | — | Ordinary Shares | 19,321 | 19,321 | D |
Explanation of responses
- F1Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- F2Restricted share units were granted on March 4, 2019, with 4,807 vesting on March 4, 2020 and 4,808 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023.
- F3The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.